Frontier Study for Adult Patients with Refractory SLE or LN
Study Title:
Amgen Frontier Study for Adult Patients with Refractory SLE or LN
Sponsor Name:
Amgen
Purpose of Study:
The purpose of the Amgen study is to assess the safety and effectiveness of the investigational medication in adults with active lupus-related kidney disease (lupus nephritis) or treatment resistant lupus, also known as refractory lupus. Refractory lupus means your condition does not respond to standard treatment options or improve despite trying different medications.
You may be able to participate in this study if you:
- Are between 18-75 years old.
- Have a confirmed diagnosis of systemic lupus erythematosus (SLE) or lupus nephritis (LN, kidney-related lupus).
- Have been told by your doctor or healthcare provider that your condition is refractory.
- Have previously failed at least two therapies.
You may not be able to participate in this study if you:
- Have had a kidney transplant.
- Have had cell-based transplants.
Other eligibility criteria apply and will be evaluated by a study doctor if you choose to continue with screening for the study.
There may be additional eligibility requirements/restrictions, which the study team will discuss with you.
What will happen during the study if you participate?
- Step 1: You will be asked to fill out an Online Questionnaire
- This questionnaire will ask for your contact information and a few questions about your medical history to determine your eligibility.
- You will be asked to select a time for a short phone call with PatientWing, a study partner helping to identify participants.
Submitting the questionnaire is voluntary and does not require a commitment to participate in the study.
- Step 2: Speak with PatientWing
- You will have a short call with PatientWing to answer additional questions about your medical history.
- PatientWing will help collect your medical records.
- Step 3: Speak With a Research Site
- After your conversation with PatientWing, you will meet the research team who will review your medical records.
- If the research team thinks you are eligible to participate, they will schedule a screening visit.
- The research team will provide more information during your conversations with them. No question is a bad question, so please share your concerns with the team!
- Step 4: Study Participation
- After you've completed the screening visit, the research team will notify you about your eligibility.
- The study doctor/study staff will provide you with more information during your screening visit appointment.
The study is being conducted at multiple clinical research sites in the United States.
Reimbursement: Participation in this study will not come at an additional cost to you. Reasonable expenses such as travel and parking may be reimbursed within reasonable limits.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. If you are a person living with lupus or a caregiver and you want to learn more about clinical trials and other research opportunities that may be right for you or your family member living with lupus, sign up for the Lupus Foundation of America’s Research Accelerated by You (RAY®) online patient and caregiver registry, if you have not already done so. Compensation is available.